Int. J. Pharm. Investigation, 2026; 16(1):12-22.
https://www.jpionline.org

Review Article

Shifting Regulatory Frameworks for Nanomedicine in the Evolution of Personalized Medicine

Lakshmi Prasanthi Nori, Chintakrindi Parvesh, Akshaya Ratna Kireeti, Jyothika Chittala, Lavanya Chintalapati, Kudeti Himaja Kasturi, Kalidindi Venkateswara Raju*

Department of Regulatory Affairs, Shri Vishnu College of Pharmacy, Bhimavaram, West Godavari, Andhra Pradesh, INDIA.

ABSTRACT

The integration of nanomedicine with personalized medicine represents a transformative paradigm in healthcare, significantly enhancing the diagnosis, treatment, and prevention of diseases. However, the regulatory framework surrounding nanomedicine presents both formidable challenges and promising opportunities, particularly given the unique characteristics of nanomaterials. This work elucidates the current regulatory mechanisms that govern nanomedicine, underscoring the necessity for specialized legislation that appropriately addresses the distinct properties of nanotechnology. Key considerations include establishing clear guidelines is essential for standardizing the definitions and classifications of nanomaterials within regulatory frameworks, suggesting comprehensive methods for assessing safety and effectiveness are imperative, ensuring consistent quality in nanomedicine products is critical for safeguarding patient safety and maintaining product reliability. Continuous monitoring after market introduction is vital to identify any long-term effects or unforeseen issues associated with nanomaterials. Addressing these regulatory complexities will facilitate the safe incorporation of nanomedicine into personalized healthcare, ultimately enhancing patient outcomes and benefiting public health.

Keywords: Nanomedicine, Nanomaterials, Personalized medicine, Nanotechnology.

Correspondence:
Dr. Kalidindi Venkateswara Raju
M. Pharm, PhD, Department of Regulatory Affairs, Shri Vishnu College of Pharmacy, Bhimavaram West Godavari, Andhra Pradesh, INDIA.
Email: venkateswararaju.k@svcp.edu.in
ORCID: 0000-0002-6279-4710

Received: 23-05-2025;
Revised: 08-07-2025;
Accepted: 19-09-2025.

INTRODUCTION

Nanomedicine as a branch of medicine progressing by applying nanoscale technologies has been described as a frontier that holds truly revolutionary potential for advancing personal medicine. It also means that at the nanoscale control of materials, diagnostic and therapeutic agents can be precisely designed to fit a particular patient's profile making treatment more effective and averted dangerous by-products. Nevertheless, there are certain obstacles in applying Nanomedicine in a clinical venue and these issues must be thoroughly discussed with regards to legal regulation of nanotechnologies (Bremer-Hoffmann, Halamoda-Kenzaoui, & Borgos, 2017).

The processes for regulating Nanomedicine are still disjointed due to the nature of nanomaterials which is quite distinct from traditional medical technologies. It is an important responsibility of the various regulatory bodies worldwide including the FDA of the United States, EMA of the European Union, and the national and regional medical bodies to come up with suitable frameworks through which they can appropriately evaluate the risks and the benefits of Nanomedicine products.There are many barriers involved in the development of the nanomedicine product as shown in Figure 1 It is crucial to bear in mind that these frameworks should consider the special features of nanomaterials, such as size, surface chemistry, and effects on biological systems, which define pharmacokinetics and bio distribution as well as potential toxicity (Devasahayam, 2019).

Another important nuance regarding the regulation of Nanomedicine in the context of personalized medicine is the trends to establish the effectiveness and safety of the new technologies as shown in Figure 2. The basic testing methodologies may not always be ideal to use for nanomaterials, to some extent requiring the creation of new testing standards for this substance. However, they face a great challenge in coming up with policies that will govern Nanomedicine bearing in mind the acceptable ethical competencies and repercussions on society such as environmental impacts, patient's consent, and equal access to the betterment treatment options in society (Mukherjee *et al.*, 2014).

Besides these, international conformity of legal measures is a relevant imperative, which will facilitate adoption and marketing of Nanomedicine across different regions. The complex nature of the regulations currently in place in the markets brings into focus the need for a coordinated effort by the regulatory authorities, the

OPEN ACCESS

Manuscript TECHNOMEDIA

DOI: 10.5530/ijpi.20260001

Publishing Partner : Manuscript Technomedia. [www.mstechnomedia.com]

industry, and academic research in an effort to develop a rational and consistent framework of policies that will foster innovation and at the same time protect consumers. This includes extending to taking on the issues of intellectual property rights linked to Nanomedicine, as the particularities of patent systems can either facilitate or hinder the development of affordable personalized medicine (Soares, Sousa, Pais, & Vitorino, 2018).

NANOMEDICINE

Nanomedicine is a highly regarded branch of medicine whose focus is based on the concepts of nanotechnology to transform medical science especially in disease detection and management. This new method makes use of nanocarriers like nanoparticles in order that drugs can directly reach the targeted cell to increase the effectiveness of treatment or a particular chemical intervention and at the same time reduce side effects. Nanomedicine also enhances diagnostic capabilities; the disease can be diagnosed in their early stages where they are easier to treat such as cancer through better imaging systems. Also, it encompasses newer treatment modalities like cationic nanoparticles for hyperthermal ablation of tumors to expunge cancerous cells and gene therapies. Despite the positive impact of Nanomedicine, there are some limitations including Safety and side effects of nanomaterials that are used in nanomedical applications, Policies and regulations and Manufacturing issues where there is need to come up with appropriate manufacturing methods for nanomaterials. Current studies seek to discover other innovative nanomaterials that can be used in medication hence underline Nanomedicine as the primary agent of change in future health care.

Nanomedicine involves the use of nanoscale materials, such as nanoparticles, nanorobots, and nanotubes, in medical applications. These materials typically range in size from 1 to 100 nm (Agrahari & Hiremath, 2017).

Applicability of nanomedicine

Nanomedicine refers to the involvement of the principles of nanotechnology within the medical field, and it has huge application in the various fields of medicine. Essential use includes drug targeting cancers or other affected tissues with the help of nanoparticles that can carry out the medications and protect from side effects and reduced therapeutic outcomes as shown in Table 1. For instance, in cancer treatment, the drug delivery facilities can be made on the nanoparticles, and these nanoparticles can be programmed to cover the malignant cells only without affecting the healthy cells. Also, Nanomedicine makes early diagnosis of diseases more effective with the help of nanoscale contrast agents and biosensors that work with medical imaging equipment's such as MRI and CT scan. Nanoparticles are also used in regenerative stem cell medicine, which help in formation of tissue engineering and scaffolding for new cell structures and tissue restoration (Boverhof *et al.*, 2015).

Various aspects of personalized medicine

Personalized medicine or Precision medicine is a new concept of healthcare that employs unique strategies to diagnose and treat the diseases rooted in patient's individual genetic profile, life conditions, and susceptibilities and the personalized medicine has many applications as shown in Table 2. This strategy is no longer a 'universal' as it is not for everyone approach, as it seeks to develop drugs and treatment plans that are more effective. Using genetic testing, it can be done that everyone has his or her distinct gene that affects the likelihood of development of a given disease, as well as the reaction to certain treatments. They have entailed the enhancement of treatment that is personal and complex with the intention of targeting unique genes that cause the disease, meaning that treatment shows better results, with less harm to the patients (Chan, 2006). Moreover, pharmacogenomics focuses on how the individual's genome influences the way he or she responds to a drug or a specific medication. It is about choosing the right medication and dosage. Nevertheless, the application of personalized medicine has issues like higher cost, concerns regarding data privacy, and complexities involved in its usage. Current and continued research on genomics, biotechnology incorporated together with data science remains to support the development of personalized medicine with hope for better distinctive healthcare system in the future.

Personalized medicine involves using information about a person's genetic makeup, proteins, and other biomarkers to diagnose and treat diseases more precisely. It moves away from the "one-size-fits-all" approach to health care (Choi & Han, 2018).

CHARACTERISTICS THAT MAKE NANOMEDICINE AN EVOLVING TECHNIQUE

The properties of Nanomedicine enable it to offer significant improvements over conventional medical technologies. By leveraging the unique characteristics of nanoscale materials-such as size, surface area, functionalization capabilities, and multi functionality-Nanomedicine can provide targeted, controlled, and highly effective treatments and diagnostics. These properties not only enhance the efficacy and safety of medical interventions but also open up new possibilities for personalized and precision medicine (Desai, 2012).

Nanomedicine exploits the unique properties of nanoscale materials to develop advanced medical applications. These properties differentiate nanomedicines from traditional therapeutic and diagnostic tools, offering significant advantages in terms of efficacy, safety, and precision. Here are the key properties of Nanomedicine:

Size and Surface Area

The average size range of nanoparticles is 1–100 nanometers. They can interact closely with biological molecules and cells

because of their small size. More surface functionalization and improved reactivity are made possible by the greater surface area in relation to volume.

Surface Functionalization

Therapeutic drugs can be delivered precisely by modifying nanoparticles with ligands, antibodies, or other molecules that attach selectively to target cells or tissues. Surface coatings like Polyethylene Glycol (PEG) can prevent immune system detection, prolonging circulation time in the bloodstream.

Controlled Release

Drugs can be encapsulated within nanoparticles, protecting them from degradation and allowing for controlled release over time. Nanoparticles can be designed to release their payload in response to specific stimuli such as pH changes, temperature, or enzymatic activity, enabling site-specific drug release.

Multi functionality

Drugs can be encased in nanoparticles to prevent deterioration and enable gradual, controlled release. Site-specific medication release is made possible by the ability of nanoparticles to release their payload in response to certain stimuli, such as temperature changes, enzyme activity, or pH variations.

Enhanced Diagnostic Capabilities

By improving the sensitivity and specificity of diagnostic tests, nanoparticles can enable earlier and more precise illness identification. Contrast agents based on nanoparticles can improve the contrast and resolution of imaging tests including PET, CT, and MRI studies.

Bio compatibility and Safety

Nanoparticles are designed to degrade into non-toxic byproducts that can be easily eliminated from the body. Careful design and material selection ensure that nanoparticles do not induce significant immune responses or toxicity.

Enhanced Permeability and Retention (EPR) Effect

The EPR effect allows nanoparticles to accumulate in tumor tissues more readily than in normal tissues, enhancing the effectiveness of cancer treatments.

Tailored Physical and Chemical Properties

Nanoparticles can be engineered with specific physical and chemical properties, such as magnetic, optical, or electrical characteristics, to suit medical applications (Keck & Müller, 2013).

PRINCIPLES OF NANOMEDICINE IN PERSONALIZED MEDICINE

Nanomedicine builds on the distinctive features of nanometer-sized objects and uses them for diagnostic, therapeutic, and monitoring purposes in medicine. First, the materials in nanotechnology have intended small-scale dimensions that provide them with compatibility and compatibility with the biological system, and, secondly, the functionalization of the surfaces for specific delivery to reduce the toxic effect and increase the efficiency of the treatment. Sustained and site-specific drug delivery can be achieved using controlled release technologies while the multipurpose features can be employed in a treatment and diagnosis all in one procedure that is referred to as theragnostic. Some specific general considerations involve biocompatibility and non-toxicity of the nanoparticles to the human body keeping in mind the concept of biodegradability. Here the predictive values include; higher sensitivity helps in the early detection of diseases and higher specificity helps in accurate detection of the diseases. The molecular characteristics of the disease process and the capacity to individualize drugs according to genetic predispositions and assess response to treatment are also essential for creating programs for personalized medicine as shown in Figure 3 (Mühlebach, Borchard, & Yildiz, 2015). Applicability of nanomedicine in propagating personalized medicine

In addition to being two of the most promising technologies for enhancing healthcare and health outcomes, nanotechnology and personalized medicine are also two of the biomedical research fields that are developing the fastest. In many present and upcoming therapeutic applications, they are also quickly convergent. Examples include the creation of nano-therapeutics that can target cell and tissue types, biosensors for proteins and other molecules *in vivo*, point-of-care molecular diagnostic devices made possible by nanotechnology, and the application of nanotechnology for better DNA sequencing and SNP analysis. A size that corresponds to the scale of the molecular substrates of personalized medicine, enhanced sensitivity in identifying and binding with target molecules, and versatility in the design and operation of the therapeutics and diagnostics at the nanoscale are just a few of the many benefits that nanotechnology offers for applications in personalized medicine. However, there is also a chance that the use of nanotechnology in customized medicine will raise questions or concerns about possible toxicity. This article discusses some of the policy, legal, and ethical concerns brought up by the combination of nanotechnology with personalized medicine, in addition to outlining the scientific and technical prospects and difficulties in doing so(Renn & Roco, 2006).

Regulatory oversight of applicability nanomedicine in personalized medicine

Regulatory perspectives on Nanomedicine in personalized medicine are pivotal due to the unique challenges these

innovations present. For example, there are classes like carbon nanotubes which are characterized with some properties that pose challenges to assessment and reevaluation procedures; in addition, products of Nanomedicine also must undergo certain regulation procedures from organizations such as the FDA and EMA before they are eased to the market. These agencies must also use numerous *in vivo* and *in vitro* tests to acquire sufficient understanding of the behavior and possible risks of nanomaterials, and pharmacokinetics and chronic effects into consideration. The synthesis of nanomedicines is complex and raises issues related to quality control, an element that must be stressed once again to improve consistency. Nonetheless, some challenges like medical, ethical, privacy, and data protection in the individualized therapy are well captured; hence, the need to come up with strong data protection laws. As a cross-sector and with international regulating agencies the complexity of such issues needs to be resolved and rendered understandable to help advance Nanomedicine therapeutics globally. Other related factors are also equally ensured and implemented to ensure the safety and efficacy of the products once they are in the market for sales. There is tightly knitted specialized regulation which can potentially contribute to faster permission as to why the safeguards are not violated and to ensure that innovative treatment with Nanomedicine is fast and safe to maintain patient treatment (Bawa, 2011).

Complexity of Nanomaterials

The complexity of nanomaterials poses significant challenges for regulatory perspectives on Nanomedicine in personalized medicine. Some elements of the regulatory approach to the function of nanomedicine in the context of personalized medicine can be referred to as crucial because of the diverse properties of nanomaterials and the opportunities presented by nanotechnologies. Given that nanomaterials are defined by their nanometer-scale size and higher surface atom count, their characteristics can differ greatly from those of bulk materials, impacting their pharmacokinetics, biodistribution, and interactions with biological systems. To address these complexities, the regulatory bodies can incorporate analysis of factors like patient compliance and usage within the traditional assessment frameworks of the FDA and EMA. This encompasses establishing new testing procedures that can effectively predict the effects, risks, and benefits of nanomaterials in general applications (Sanvicens & Marco, 2008). The first aspect seems to be one of the most difficult obstacles, which is the great variability of nanomaterials depending on their size, form, surface, and chemical composition. That is why the attempt to standardize and improve the quality of peptides presented in this paper becomes so challenging since variations in sequences may have profound effects on the behavior and therapeutic properties of these compounds. The characterization methodology to be applied should be standardized so that regulatory agencies are able to define plainly for producers what constitutes a nanomaterial (Gaspar, 2007). Further, there are certain characteristics associated with nanomaterials that creates some Bonafide safety issues Different characteristics make nanomaterials quite different in terms of safety features there are some of these characteristics include ability to cross biological barriers and nanomaterial have high surface area to volume ratio. These are, for example, toxicity, unforeseen immune reactions, and ever-damaging effects on the environment. Developers must adopt a rigorous Preclinical and clinical development plan to assess these risks adequately. It means interdisciplinary cooperation can help untangle the challenges of nanomaterials in individualizing treatments. It incorporates an integrated system that would identify inputs from material scientists, toxicologists, clinicians, and regulatory bodies in developing comprehensive assessment tools. Also, there is a growing need to advance new strategies in analyzing and assessing nanomaterials together with the calls to improve better and sophisticated techniques in evaluating nanomaterials constantly. Thus, investing in changes of principles of regulations and, in particular, development of principles of new nanomaterials regulation would be profitable for regulatory bodies as for the development of new strategies, priorities, and approaches for Nanomedicine regulation in the field of personalized medicine. This means dealing with issues arising from the multiple personalities of nanomaterials, standardizing testing procedures

Table 1: Applications of nanomedicine.

Nanomedicine in the clinic	"Liposome" ("30-100 nm") "Nanoparticle" ("Ironoxide," "5-50 nm")	"Targeted drug Delivery" "Contrast agent for magnetic resonance imaging"	"Cancer" "Hepatic" (Liver)
Nanomedicines under development	"Dendrimer" (5-50 nm) "Fullerene" ("Carbonbucky ball" 2-20 nm) "Nanoshells" ("Goldcoated silica" 60 nm)	"Contrast agent for magnetic resonance imaging" Antioxidant "Hyperthermia"	"Cardiovascular" "Phase III clinical Trial" Neurodegenerative, Cardiovascular "Cancer" "Preclinical"

for these novel therapies, and seeking proper integration from those involved in handling these novel therapies (Bawa, Melethil, Simmons, & Harris, 2008).

Safety and efficacy

The potential risks and benefits of Nanomedicine in personalized medicine created the need for proper regulation of nanotechnology in medicine by the regulatory authorities like the FDA and EMA due to the peculiar features of nanomaterial. These are materials with sizes that are very small and hence possess high surface area to volume ratio and how they interact with biological systems is in a special manner hence a different regulatory measure needs to be taken. These features encompass issues such as toxicity measures, immune system analysis, and long-term outcomes analysis; before which *in vitro* and *in vivo* tests are required to reduce all possible safety risks 5. Measures of efficacy pertain to immense studies on PK profiles, establishing therapeutic accomplishment through highly controlled and standardized clinical trial processes, and guaranteeing the like-kind reproduction of Nanomedicine products. Testing had thus become resilient to regulatory frameworks' standardization requirements, and these frameworks must adapt and develop testing specific protocols and promote multidisciplinary synergies (Saha, 2009).

Regulatory Approaches for Safety and efficacy

Innovative Testing Protocols

Regulators need to develop and implement innovative testing protocols tailored to the unique properties of nanomaterials. These protocols should address the specific challenges posed by the size, surface properties, and interaction of nanomaterials with biological systems.

Interdisciplinary Collaboration

Effective regulation of Nanomedicine in personalized medicine requires interdisciplinary collaboration. Regulators work closely with scientists, clinicians, and industry stakeholders to develop comprehensive guidelines and ensure that all aspects of Nanomedicine safety and efficacy are thoroughly evaluated.

Adaptive Regulatory Frameworks

As Nanomedicine is a rapidly evolving field, regulatory frameworks must be adaptive and flexible. Agencies like the FDA and EMA are developing specialized pathways, such as the FDA's Breakthrough Therapy designation, to expedite the review and approval of promising Nanomedicine therapies while maintaining high safety and efficacy standards (Swapna, Sree, & Mahitha, 2023).

Standardization and quality control

Standardization and quality control are crucial regulatory aspects for Nanomedicine in personalized medicine due to the inherent complexity and variability of nanomaterials. Regulatory bodies like the FDA and EMA face significant challenges in ensuring the consistency and reproducibility of Nanomedicine products, necessitating the development of stringent guidelines and protocols.

Standardization

Characterization of Nanomaterials

Standardization begins with the thorough characterization of nanomaterials. Regulatory agencies require detailed information on the size, shape, surface properties, composition, and stability of nanomaterials. This comprehensive characterization is essential

Table 2: Applications for personalized medicine

Sl. No.	Application	Description
1	Pharmacogenomics	Tailoring drug treatments based on individual genetic profiles to optimize efficacy and minimize side effects.
2	Targeted Therapies	Developing treatments that specifically target molecular and genetic markers of diseases, such as specific cancer mutations.
3	Genetic Testing	Using genetic tests to predict disease risk, guide prevention strategies, and inform early diagnosis.
4	Biomarker Identification	Identifying and using biomarkers to monitor disease progression and treatment response.
5	Personalized Vaccines	Designing vaccines based on an individual's genetic makeup to enhance immune response.
6	Gene Therapy	Treating or preventing disease by directly altering genes, such as using CRISPR to correct genetic mutations.
7	Patient-Specific Diagnostics	Developing diagnostic tools tailored to the genetic and molecular profile of the patient.
8	Precision Surgery	Utilizing detailed genetic and molecular information to guide surgical decisions and techniques.
9	Nutrigenomics	Creating personalized nutrition plans based on individual genetic profiles to improve health and prevent disease.
10	Reproductive Medicine	Applying genetic screening and other technologies to assist in family planning, such as selecting embryos without genetic diseases.

for understanding how nanomaterials will behave in biological systems and for ensuring that they meet predefined specifications.

Analytical Methods

The development and validation of analytical methods are vital for standardization. These methods must be capable of accurately measuring and monitoring the properties of nanomaterials throughout the manufacturing process. Regulatory agencies work to establish standardized analytical techniques that can be consistently applied across different laboratories and production facilities.

International Harmonization

Standardization efforts also involve international harmonization. Organizations such as the International Organization for Standardization (ISO) and the International Council for Harmonization (ICH) play a key role in developing global standards for nanomaterials. Harmonized standards facilitate the global development, approval, and commercialization of Nanomedicine products, ensuring consistency across different regulatory jurisdictions (Dri, Rinaldi, Carafa, & Marianecci, 2023).

Quality Control

Manufacturing Processes

Quality control in Nanomedicine manufacturing is critical to ensure batch-to-batch consistency. Regulatory agencies require stringent oversight of manufacturing processes, including the raw materials used, production methods, and final product testing. Good Manufacturing Practice (GMP) guidelines are adapted to address the specific challenges of producing nanomaterials.

Quality Assurance Systems

Implementing robust quality assurance systems is essential for maintaining high standards in Nanomedicine production. These systems include comprehensive documentation, regular audits, and continuous monitoring to ensure that all aspects of the manufacturing process adhere to regulatory requirements and industry best practices.

Lot Release Testing

Before Nanomedicine products can be released to the market, they must undergo rigorous release testing. This test ensures that each batch meets the established safety, efficacy, and quality standards. It includes evaluating the physicochemical properties, purity, potency, and sterility of the nanomaterials (Vizirianakis, 2011).

Necessity of harmonization of regulatory guidelines with respect to applying nanomedicine in personalized medicine

Global harmonization in regulatory perspectives on Nanomedicine in personalized medicine is essential for ensuring the efficient development and approval of innovative therapies while maintaining high standards of safety and efficacy. By aligning regulatory requirements and standards across different regions, redundant testing and documentation are minimized, accelerating the approval process for Nanomedicine products. This harmonization also facilitates international collaboration, enabling regulatory agencies to share information and collaborate on safety assessments and post-market surveillance efforts. Streamlining approval processes through mutual recognition agreements and adaptive pathways allows for faster access to



Figure 1: Barriers for the development of Nanomedicine product.



Figure 2: A schematic representation of nanotechnology used in personalized medicine.

cutting-edge treatments while ensuring patient safety. Despite challenges such as differences in regulations and cultural considerations, continued collaboration and education efforts are crucial for advancing global harmonization initiatives. Overall, global harmonization promotes consistency, transparency, and accessibility in the regulatory landscape of Nanomedicine, ultimately benefiting patients worldwide (Marchant, 2009).

Ethical and privacy concerns

Both ethics and privacy issues remain important in the potential regulation of Nanomedicine applied in personalized medicine because genes are personal and sensitive and nanomaterials pose their own hazard. Regulatory bodies should incorporate thorough informed consent mechanisms and stress on enhancing the understanding of people of the possible risks involved and benefits that can be obtained from the treatments based on Nanomedicine. Two of the major problems that all the advanced therapies should address if they are to avoid contributing to deepening of equity and access, are: Misconceptions, as well as the long-term consequences and questions, still should be closely monitored to preserve the wellbeing of patients. Due to data privacy issues, Genetic information should not fall in the wrong hands and therefore data protection laws should be very strict especially concerning the use of Genetic information, this further influences the way data can be shared and used, that is why there are several protocols which insist on use of double consent when sharing patients' Genetic information and how data is anonymized. Also, there is a need for proper and adequate measures on security to guard patients' information, and needs for protection on genetic information from being used in other related area that has no affection with health issues. These ethical and private concerns must be coordinated into these regulatory architectures at large to protect the patient's rights and sustain the public's confidence in novel promises of Nanomedicine as shown in Figures 4 and 5 (Jain, 2010).

Interdisciplinary Collaboration

Interdisciplinary collaboration is fundamental in shaping regulatory perspectives on Nanomedicine in personalized medicine. Bringing together experts from diverse fields such as materials science, biology, clinical medicine, ethics, and regulatory affairs enables a comprehensive understanding of the complex issues at play. Scientists provide insights into the unique properties of nanomaterials, clinicians offer practical perspectives on patient care, ethicists contribute to the development of ethical guidelines, and regulatory experts ensure that frameworks are effective and responsive. Additionally, collaboration with industry partners ensures that regulatory requirements are practical and feasible for product development and commercialization. By working collaboratively across disciplines, regulatory bodies can develop informed and balanced frameworks that promote the safe, effective, and ethical use of Nanomedicine for personalized healthcare, ultimately benefiting patients and advancing medical science as shown in Figure 6 (Chapman, 2005).

REGULATORY PATHWAYS APPLICABLE FOR NANOMEDICINE IN PERSONALIZED MEDICINE

Regulatory pathways play a crucial role in shaping the landscape of Nanomedicine in personalized medicine by providing frameworks for the development, evaluation, and approval of these innovative therapies. These pathways outline the steps and requirements for bringing Nanomedicine products to market while ensuring safety, efficacy, and compliance with regulatory standards.

Traditional Approval Pathways

Traditional approval processes set up by regulatory bodies like the FDA and EMA may be used to evaluate nanomedicine products. Clinical trials, preclinical testing, and submitting a New Drug Application (NDA) or Marketing Authorization Application (MAA) for regulatory approval are all part of this process.

Accelerated Approval Programs

Regulatory agencies offer accelerated approval programs to expedite the development and availability of promising therapies for serious or life-threatening conditions. Nanomedicine products may qualify for these programs if they demonstrate substantial improvement over existing treatments, allowing for faster review and approval.

Breakthrough Therapy Designation

The FDA's Breakthrough Therapy designation is available for therapies that show significant improvement in treating serious conditions compared to available treatments. Nanomedicine products with this design benefit from enhanced regulatory support and expedited review processes to facilitate their development and approval.



Figure 3: Principles of Nanomedicine in personalized medicine



Figure 4: Efficacy concerns.



Figure 5: Safety concerns.



Figure 6: Interdisciplinary collaboration.

Orphan Drug Designation

Nanomedicine products targeting rare diseases may qualify for orphan drug designation, providing incentives such as market exclusivity and tax credits to encourage their development and commercialization.

Fast Track Designation

Regulatory agencies offer fast track designation to expedite the development and review of therapies for serious conditions with unmet medical needs. Nanomedicine products may receive fast track designation if they address such unmet needs, accelerating their development and regulatory review.

Adaptive Pathways

Adaptive pathways allow for flexible and iterative development approaches, particularly suited for innovative therapies like Nanomedicine in personalized medicine. These pathways enable developers to adapt their development strategies based on emerging data and stakeholder input, facilitating the timely availability of these therapies to patients.



Figure 7: Challenges in nanomedicine and personalized medicine.

Regenerative Medicine Advanced Therapy (RMAT) Designation

The FDA's RMAT designation is available for regenerative medicine products, including some Nanomedicine therapies, intended to treat serious conditions. RMAT designation provides similar benefits to Breakthrough Therapy designation, expediting development and review processes.

Regulatory pathways play a vital role in facilitating the development and approval of Nanomedicine therapies in personalized medicine. These pathways offer opportunities for expedited review, enhanced regulatory support, and flexibility in development strategies, ultimately advancing the availability of innovative therapies to patients in need (Thapa & Kim, 2023).

PROSPECTS OF NANOMEDICINE

Future advancements in Nanomedicine in the context of personalized medicine will have great opportunities for the regulation of the developments in the field to enforce the safety, efficiency, and quality of the innovative approaches. It is the order of the day to expect refractory bodies like the FDA and EMA to provide elaborate and more particular directives that will captivate the spatial and temporal disposition of nanomaterials within biological systems. Greater frameworks shall comprise of intensive measuring techniques and production line establishment to guarantee the production of standard and powerfully built products. Probably, enhanced cooperation between scientists, clinicians, regulators as well as representatives of industry will be a key to the advancement of the therapies and making procedures faster. Moreover, the integration of more sophisticated characterization and testing procedures, as well as analytical approaches and high-fidelity Preclinical simulation models, will become commonplace to forecast nanomedicine's interactions within the human body. Since Nanomedicine will play a dominant role in the future of individualized medicine, corresponding legal policies will call for patient-oriented approaches, which will guarantee that the treatments would address each patient's requirements and quality, while adhering to safety and efficiency benchmarks. Such ever-shifting regulatory objectives work towards achieving innovation along with strict monitoring, the key goal of which is the improvement of patient care measures in the field of personalized medicines (Malviya *et al.*, 2021).

CHALLENGES IN NANOMEDICINE AND PERSONALIZED MEDICINE

In studying Nanomedicine practice, the field is situated within a complex mosaic of frameworks that may transverse scientific, technology, legal, and even ethical fields as shown in Figure 7. Some important issues are; absence of definition or standard of nanoparticles or the need to classify nanoparticles since the properties of almost all nanoparticles differ in some ways and yet these must be measured and quantified. This last aspect can be considered as one of the main challenges: stability is crucial since nanoparticles are known to cluster or else degrade when stored or when scaled up from the laboratory setting to the manufacturing level. The use of nanoparticles has drawbacks since it comprises smaller molecules which make it difficult to determine their safety levels and could lead to several biological effects that could be toxic; this is why toxicity analysis is important. Some of the current challenges in Nanomedicine are that clearly, the nanoparticles can only be located at specific locations in the body and more to the point, there is always a challenge of how best

to deliver these nanoparticles without negative impacting on the rest of the surrounding cells. Newer outlets add further issues, and they must go out of their way to demonstrate the safety and efficacy of their products, even for relatively new outlets. There are other questions that must be raised, including the ethical factor: voluntary informed consent and the possible repercussions that follow. For any kind of advancement on nanomedicines from a lab perspective and translating same to an actual pragmatic perspective to improve patients care and therefore establishing brand new frontiers in medical technology innovation; these actors must interact and engage in meanings making processes that are coordinated and in phase (Hertig *et al*., 2021; Mühlebach, 2018).

CONCLUSION

Regulatory perspectives on Nanomedicine in personalized medicine are crucial for ensuring safety, efficacy, and ethical integrity. Key regulatory challenges include characterizing nanomaterials, standardizing manufacturing processes, and assessing efficacy and safety profiles. Robust methodologies for characterizing nanomedicines are essential, alongside stringent standards for manufacturing and quality control. Adapted assessment frameworks must capture the unique attributes of nanomedicines, ensuring thorough evaluation of efficacy and safety. Ethical considerations, such as patient data privacy and equitable access, require careful attention to upholding ethical principles in personalized medicine. To overcome these obstacles and enable the ethical incorporation of nanomedicine into individualized treatment, which will eventually improve patient outcomes, cooperation between regulatory bodies, researchers, and industry stakeholders is crucial.

ACKNOWLEDGEMENT

The authors are thankful to Shri Vishnu College of Pharmacy, Bhimavaram for providing the necessary facilities.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

REFERENCES

Agrahari, V., & Hiremath, P. (2017). Challenges associated and approaches for successful translation of nanomedicines into commercial products. Nanomedicine, 12(8), 819-823. https://doi.org/10.2217/nnm-2017-0039

Bawa, R. (2011). Regulating nanomedicine-Can the FDA handle it? Current Drug Delivery, 8(3), 227-234. https://doi.org/10.2174/156720111795256156

Bawa, R., Melethil, S., Simmons, W. J., & Harris, D. (2008). Nanopharmaceuticals-Patenting issues and FDA regulatory challenges. The Scitech Lawyer, 5(2), 10-15. https://doi.org/10.2139/ssrn.3444847

Boverhof, D. R., Bramante, C. M., Butala, J. H., Clancy, S. F., Lafranconi, M., West, J., & Gordon, S. C. (2015). Comparative assessment of nanomaterial definitions and safety evaluation considerations. Regulatory Toxicology and Pharmacology, 73(1), 137-150. https://doi.org/10.1016/j.yrtph.2015.06.001

Bremer-Hoffmann, S., Halamoda-Kenzaoui, B., & Borgos, S. E. F. (2016). Identification of regulatory needs for nanomedicines (EUR 28224 EN). Publications Office of the European Union. https://doi.org/10.2788/585950

Chan, V. S. W. (2006). Nanomedicine: An unresolved regulatory issue. Regulatory Toxicology and Pharmacology, 46(3), 218-224. https://doi.org/10.1016/j.yrtph.2006.04.009

Chapman, P. (2005). Nanotechnology in the pharmaceutical industry. Expert Opinion on Therapeutic Patents, 15(3), 249-251. https://doi.org/10.1517/13543776.15.3.249

Choi, Y. H., & Han, H.-K. (2018). Nanomedicines: Current status and future perspectives in aspect of drug delivery and pharmacokinetics. Journal of Pharmaceutical Investigation, 48(1), 43-60. https://doi.org/10.1007/s40005-017-0370-4

Desai, N. (2012). Challenges in development of nanoparticle-based therapeutics. The AAPS Journal, 14(2), 282-295. https://doi.org/10.1208/s12248-012-9339-4

Devasahayam, S. (2019). Nanotechnology and nanomedicine in market. In S. S. Mohapatra, S. Ranjan, N. Dasgupta, R. K. Mishra, & S. Thomas (Eds.),Characterization and biology of nanomaterials for drug delivery (pp. 477-522). Elsevier. https://doi.org/10.1016/B978-0-12-814031-4.00017-9

Dri, D. A., Rinaldi, F., Carafa, M., & Marianecci, C. (2023). Nanomedicines and nanocarriers in clinical trials: Surfing through regulatory requirements and physicochemical critical quality attributes. Drug Delivery and Translational Research, 13(3), 757-769. https://doi.org/10.1007/s13346-022-01262-y

Gaspar, R. (2007). Regulatory issues surrounding nanomedicines: Setting the scene for the next generation of nanopharmaceuticals. Nanomedicine, 2(2), 143-147. https://doi.org/10.2217/17435889.2.2.143

Hertig, J. B., Shah, V. P., Flühmann, B., Mühlebach, S., Stemer, G., Surugue, J., Moss, R., & Di Francesco, T. (2021). Tackling the challenges of nanomedicines: Are we ready? American Journal of Health-System Pharmacy, 78(12), 1047-1056. https://doi.org/10.1093/ajhp/zxab048

Jain, K. K. (2010). Innovative diagnostic technologies and their significance for personalized medicine. Molecular Diagnosis and Therapy, 14(3), 141-147. https://doi.org/10.1007/BF03256366

Keck, C. M., & Müller, R. H. (2013). Nanotoxicological classification system (NCS)-A guide for the risk-benefit assessment of nanoparticulate drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 84(3), 445-448. https://doi.org/10.1016/j.ejpb.2013.01.001

Malviya, R., Fuloria, S., Verma, S., Subramaniyan, V., Sathasivam, K. V., Kumarasamy, V., Hari Kumar, D. H., Vellasamy, S., Meenakshi, D. U., Yadav, S., Sharma, A., & Fuloria, N. K. (2021). Commercial utilities and future perspective of nanomedicines. PeerJ, 9, Article e12392. https://doi.org/10.7717/peerj.12392

Marchant, G. E. (2009). Small is beautiful: What can nanotechnology do for personalized medicine? Current Pharmacogenomics and Personalized Medicine, 7(4), 231-237. https://doi.org/10.2174/187569209790112346

Mühlebach, S. (2018). Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach? Advanced Drug Delivery Reviews, 131, 122-131. https://doi.org/10.1016/j.addr.2018.06.024

Mühlebach, S., Borchard, G., & Yildiz, S. (2015). Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars. Nanomedicine, 10(4), 659-674. https://doi.org/10.2217/nnm.14.189

Mukherjee, B., Dey, N. S., Maji, R., Bhowmik, P., Das, P. J., & Paul, P. (2014). Current status and future scope for nanomaterials in drug delivery. In A. D. Sezer (Ed.),Application of nanotechnology in drug delivery (pp. 1-30). IntechOpen. https://doi.org/10.5772/58450

Renn, O., & Roco, M. C. (2006). Nanotechnology and the need for risk governance. Journal of Nanoparticle Research, 8(2), 153-191. https://doi.org/10.1007/s11051-006-9092-7

Saha, M. (2009). Nanomedicine: Promising tiny machine for the healthcare in future-A review. Oman Medical Journal, 24(4), 242-247. https://doi.org/10.5001/omj.2009.50

Sanvicens, N., & Marco, M. P. (2008). Multifunctional nanoparticles-Properties and prospects for their use in human medicine. Trends in Biotechnology, 26(8), 425-433. https://doi.org/10.1016/j.tibtech.2008.04.005

Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018). Nanomedicine: Principles, properties, and regulatory issues. Frontiers in Chemistry, 6, 360. https://doi.org/10.3389/fchem.2018.00360

Swapna, G., Mahitha, M., & Teja Sree, P. (2023). Applications of nanotechnology in drug development. Austin Pharmacology & Pharmaceutics, 7(1), 1024. https://doi.org/10.26420/austinpharmacolpharm.2023.1024

Thapa, R. K., & Kim, J. O. (2023). Nanomedicine-based commercial formulations: Current developments and future prospects. Journal of Pharmaceutical Investigation, 53(1), 19-33. https://doi.org/10.1007/s40005-022-00607-6

Vizirianakis, I. S. (2011). Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. Nanomedicine: Nanotechnology, Biology, and Medicine, 7(1), 11-17. https://doi.org/10.1016/j.nano.2010.11.002.

Cite this article: Nori LP, Parvesh C, Kireeti AR, Chittala J, Chintalapati L, Kasturi KH, *et al*. Shifting Regulatory Frameworks for Nanomedicine in the Evolution of Personalized Medicine. Int. J. Pharm. Investigation. 2026;16(1):12-22.